Sangamo Biosciences (SGMO) Gets a Hold Rating from Wedbush

By Jason Carr

In a report released today, Liana Moussatos from Wedbush reiterated a Hold rating on Sangamo Biosciences (SGMOResearch Report), with a price target of $11.00. The company’s shares closed last Monday at $9.75.

According to, Moussatos has currently no stars on a ranking scale of 0-5 stars, with an average return of -12.4% and a 33.8% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.

Currently, the analyst consensus on Sangamo Biosciences is a Moderate Buy with an average price target of $13.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $13.91 and a one-year low of $6.26. Currently, Sangamo Biosciences has an average volume of 1.13M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sangamo Therapeutics, Inc. engages in researching and developing transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.